After Dexcom reported higher than expected Q3 revenue but said it does not expect its 2016 revenue to come in above its previous guidance range, BMO Capital analyst Joanne Wuensch says that the company's Q4 and 2017 results will probably be negatively impacted by Medtronic's (MDT) upcoming MiniMed 670G product. Nonetheless, the analyst says that the pending non-adjunctive label for Dexcom's CGM "can make waves," while it has "ample" room for growth in its "vastly underserved" market, as its "technology is nowhere near its full potential." The analyst cut her price target on the shares to $90 from $112 but keeps an Outperform rating on the stock.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.